JP2005526084A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005526084A5 JP2005526084A5 JP2003575990A JP2003575990A JP2005526084A5 JP 2005526084 A5 JP2005526084 A5 JP 2005526084A5 JP 2003575990 A JP2003575990 A JP 2003575990A JP 2003575990 A JP2003575990 A JP 2003575990A JP 2005526084 A5 JP2005526084 A5 JP 2005526084A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- mbl
- composition according
- pharmaceutically acceptable
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 45
- 102000009112 Mannose-Binding Lectin Human genes 0.000 claims 31
- 108010087870 Mannose-Binding Lectin Proteins 0.000 claims 31
- 239000000654 additive Substances 0.000 claims 9
- 230000000996 additive effect Effects 0.000 claims 8
- 102000004169 proteins and genes Human genes 0.000 claims 8
- 108090000623 proteins and genes Proteins 0.000 claims 8
- 239000000243 solution Substances 0.000 claims 8
- 239000003381 stabilizer Substances 0.000 claims 7
- 239000000725 suspension Substances 0.000 claims 7
- 239000000872 buffer Substances 0.000 claims 6
- 150000001768 cations Chemical class 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 208000015181 infectious disease Diseases 0.000 claims 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 2
- -1 CaCl 2 Substances 0.000 claims 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 2
- 239000004471 Glycine Substances 0.000 claims 2
- 102100026061 Mannan-binding lectin serine protease 1 Human genes 0.000 claims 2
- 229930195725 Mannitol Natural products 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- 239000002577 cryoprotective agent Substances 0.000 claims 2
- 238000001802 infusion Methods 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 239000007951 isotonicity adjuster Substances 0.000 claims 2
- 239000000594 mannitol Substances 0.000 claims 2
- 235000010355 mannitol Nutrition 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 210000002966 serum Anatomy 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-M Aminoacetate Chemical compound NCC([O-])=O DHMQDGOQFOQNFH-UHFFFAOYSA-M 0.000 claims 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 1
- 229920002307 Dextran Polymers 0.000 claims 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims 1
- 101001055956 Homo sapiens Mannan-binding lectin serine protease 1 Proteins 0.000 claims 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 1
- 101710117390 Mannan-binding lectin serine protease 1 Proteins 0.000 claims 1
- 102100026046 Mannan-binding lectin serine protease 2 Human genes 0.000 claims 1
- 101710117460 Mannan-binding lectin serine protease 2 Proteins 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical group C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims 1
- 229920001213 Polysorbate 20 Polymers 0.000 claims 1
- 229920001214 Polysorbate 60 Polymers 0.000 claims 1
- 108010022999 Serine Proteases Proteins 0.000 claims 1
- 102000012479 Serine Proteases Human genes 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims 1
- 239000007983 Tris buffer Substances 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 229960005070 ascorbic acid Drugs 0.000 claims 1
- 235000010323 ascorbic acid Nutrition 0.000 claims 1
- 239000011668 ascorbic acid Substances 0.000 claims 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 1
- 239000006172 buffering agent Substances 0.000 claims 1
- 230000003139 buffering effect Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 229960001031 glucose Drugs 0.000 claims 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 1
- 238000010255 intramuscular injection Methods 0.000 claims 1
- 239000007927 intramuscular injection Substances 0.000 claims 1
- 238000010253 intravenous injection Methods 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 229960000502 poloxamer Drugs 0.000 claims 1
- 229920001983 poloxamer Polymers 0.000 claims 1
- 229940050929 polyethylene glycol 3350 Drugs 0.000 claims 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 1
- 229920000053 polysorbate 80 Polymers 0.000 claims 1
- 239000012460 protein solution Substances 0.000 claims 1
- 238000011946 reduction process Methods 0.000 claims 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 claims 1
- 238000010254 subcutaneous injection Methods 0.000 claims 1
- 239000007929 subcutaneous injection Substances 0.000 claims 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 239000012929 tonicity agent Substances 0.000 claims 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200200414 | 2002-03-15 | ||
| PCT/DK2003/000179 WO2003077937A1 (en) | 2002-03-15 | 2003-03-14 | Pharmaceutical compositions comprising mannose binding lectin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005526084A JP2005526084A (ja) | 2005-09-02 |
| JP2005526084A5 true JP2005526084A5 (enExample) | 2006-01-26 |
Family
ID=27763313
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003575990A Pending JP2005526084A (ja) | 2002-03-15 | 2003-03-14 | マンノース結合レクチンを含む医薬組成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US7462596B2 (enExample) |
| EP (1) | EP1344533B1 (enExample) |
| JP (1) | JP2005526084A (enExample) |
| CN (1) | CN1652813A (enExample) |
| AT (1) | ATE337014T1 (enExample) |
| AU (1) | AU2003215524A1 (enExample) |
| DE (1) | DE60307701T2 (enExample) |
| DK (1) | DK1344533T3 (enExample) |
| ES (1) | ES2271515T3 (enExample) |
| PT (1) | PT1344533E (enExample) |
| WO (1) | WO2003077937A1 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003002136A2 (en) | 2001-06-28 | 2003-01-09 | Novo Nordisk A/S | Stable formulation of modified glp-1 |
| GB0222014D0 (en) * | 2002-09-23 | 2002-10-30 | Leuven K U Res & Dev | Mannan-binding lectin |
| KR101308912B1 (ko) | 2003-06-03 | 2013-09-23 | 노보 노르디스크 에이/에스 | 안정화된 약학적 펩티드 조성물 |
| PL1633391T3 (pl) | 2003-06-03 | 2012-03-30 | Novo Nordisk As | Stabilizowane farmaceutycznie kompozycje peptydowe |
| DK3300721T4 (da) | 2003-11-20 | 2025-03-03 | Novo Nordisk As | Propylenglycol-holdige peptidformuleringer hvilke er optimale til fremstilling og til anvendelse i injektionsindretninger |
| US7335633B2 (en) * | 2004-01-12 | 2008-02-26 | Cornell Research Foundation, Inc. | Detecting recurrent vulvovaginal candidiasis or vulvar vestibulitis syndrome and method for treating same |
| EP1618887A1 (en) * | 2004-07-12 | 2006-01-25 | UMC Utrecht Holding B.V. | Clearance of polyols from the body |
| PL1789434T3 (pl) | 2004-08-31 | 2014-07-31 | Novo Nordisk As | Zastosowanie tris(hydroksymetylo)aminometanu do stabilizacji peptydów, polipeptydów i białek |
| MX2007005521A (es) | 2004-11-12 | 2007-05-18 | Novo Nordisk As | Formulaciones estables de peptidos insulinotropicos. |
| WO2006071102A1 (en) * | 2004-12-30 | 2006-07-06 | Dobeel Co., Ltd. | Spray-dried composition containing collectin family proteins or variants therof and process for preparing the same |
| EP1874333A2 (en) * | 2005-04-11 | 2008-01-09 | Natimmune A/S | Mannan-binding lectin (mbl) in the treatment of immunocompromised conditions asssociated with cancer |
| TW200727900A (en) * | 2005-07-27 | 2007-08-01 | Yakult Honsha Kk | Aqueous solution preparation containing camptothecins |
| US20090304686A1 (en) * | 2006-03-08 | 2009-12-10 | Universotair Medisch Centrum Utrecht | Interfering in activation of an immune cell by influencing interaction of lair and collagen |
| HRP20160625T1 (hr) * | 2007-09-10 | 2016-08-12 | Boston Biomedical, Inc. | Novi inhibitori stat3 signalnog puta i inhibitori matičnih stanica raka |
| GB0821806D0 (en) * | 2008-11-28 | 2009-01-07 | Circassia Ltd | Compositions with reduced dimer formation |
| US20120282285A1 (en) | 2009-07-17 | 2012-11-08 | Rigshospitalet | Masp isoforms as inhibitors of complement activation |
| SG10201503351RA (en) | 2010-01-19 | 2015-06-29 | Harvard College | Engineered Opsonin for Pathogen Detection and Treatment |
| ES2987670T3 (es) | 2010-03-19 | 2024-11-15 | 1Globe Biomedical Co Ltd | Métodos novedosos para actuar sobre células madre cancerosas |
| AU2012284097B2 (en) | 2011-07-18 | 2017-08-03 | President And Fellows Of Harvard College | Engineered microbe-targeting molecules and uses thereof |
| WO2013130875A1 (en) | 2012-02-29 | 2013-09-06 | President And Fellows Of Harvard College | Rapid antibiotic susceptibility testing |
| BR112014031522A2 (pt) * | 2012-06-18 | 2017-08-01 | Omeros Corp | métodos para inibir a ativação de complemento dependente de masp-3, para inibir a ativação de complemento dependente de masp-2 e para fabricar um medicamento |
| WO2014144325A1 (en) | 2013-03-15 | 2014-09-18 | President And Fellows Of Harvard College | Methods and compositions for improving detection and/or capture of a target entity |
| CA2908380A1 (en) | 2013-04-09 | 2014-10-16 | Boston Biomedical, Inc. | Methods for treating cancer |
| JP6649250B2 (ja) | 2013-05-21 | 2020-02-19 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | 操作されたヘム結合性構成物およびその使用 |
| US10513546B2 (en) | 2013-12-18 | 2019-12-24 | President And Fellows Of Harvard College | CRP capture/detection of gram positive bacteria |
| EP3331549B1 (en) | 2015-08-06 | 2020-12-23 | President and Fellows of Harvard College | Improved microbe-binding molecules and uses thereof |
| WO2018102427A1 (en) | 2016-11-29 | 2018-06-07 | Boston Biomedical, Inc. | Naphthofuran derivatives, preparation, and methods of use thereof |
| WO2018213424A1 (en) | 2017-05-17 | 2018-11-22 | Boston Biomedical, Inc. | Methods for treating cancer |
| KR102665710B1 (ko) | 2017-08-24 | 2024-05-14 | 노보 노르디스크 에이/에스 | Glp-1 조성물 및 그 용도 |
| CN110755601B (zh) * | 2019-10-31 | 2023-06-23 | 云南康洲生物科技有限公司 | 一种治疗hiv/aids免疫重建缺陷的芸豆凝集素植物药组合物和制备方法及其应用 |
| JP7761567B2 (ja) | 2020-02-18 | 2025-10-28 | ノヴォ ノルディスク アー／エス | 医薬製剤 |
| JP2024537924A (ja) * | 2021-10-01 | 2024-10-16 | インスティテュート オブ ケミストリー、テクノロジー アンド メタラジー | サバリア・サバグリアの炭水化物結合ポリペプチド |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4707231B2 (ja) * | 1998-06-10 | 2011-06-22 | スタテンズ セーラム インスティテュート | マンナン結合レクチンを製造するための精製方法及びｍｂｌ医薬品 |
| DK1084143T3 (da) * | 1998-06-10 | 2006-12-27 | Statens Seruminstitut | Oprensningsproces til fremstilling af mannanbindende lectin og et medicinsk MBL-produkt |
| US6297024B1 (en) * | 1998-10-15 | 2001-10-02 | Cell Activation, Inc. | Methods for assessing complement activation |
| DE60030173T2 (de) * | 1999-05-14 | 2007-08-23 | Steffen Thiel | Neue Indikationen für Mannan-binding Lectin (MBL) zur Behandlung von immungeschwächten Patienten |
| US7211396B2 (en) * | 2002-04-18 | 2007-05-01 | Antibodyshop A/S | Antibody pairs and kits for immunochemical determination of mannan-binding lectin |
-
2003
- 2003-03-14 AU AU2003215524A patent/AU2003215524A1/en not_active Abandoned
- 2003-03-14 DE DE60307701T patent/DE60307701T2/de not_active Expired - Fee Related
- 2003-03-14 PT PT03388016T patent/PT1344533E/pt unknown
- 2003-03-14 JP JP2003575990A patent/JP2005526084A/ja active Pending
- 2003-03-14 EP EP03388016A patent/EP1344533B1/en not_active Expired - Lifetime
- 2003-03-14 US US10/388,322 patent/US7462596B2/en not_active Expired - Fee Related
- 2003-03-14 CN CNA038105802A patent/CN1652813A/zh active Pending
- 2003-03-14 ES ES03388016T patent/ES2271515T3/es not_active Expired - Lifetime
- 2003-03-14 WO PCT/DK2003/000179 patent/WO2003077937A1/en not_active Ceased
- 2003-03-14 DK DK03388016T patent/DK1344533T3/da active
- 2003-03-14 AT AT03388016T patent/ATE337014T1/de not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005526084A5 (enExample) | ||
| JP4879104B2 (ja) | 高度に濃縮された、凍結乾燥された、および液体の、因子ｉｘ処方 | |
| JP4789698B2 (ja) | 因子ｉｘ用処方 | |
| ES2887187T3 (es) | Formulaciones de VWF recombinante | |
| KR101212025B1 (ko) | 인자 ⅶ 폴리펩티드의 안정화된 고체 조성물 | |
| KR100457485B1 (ko) | 안정한 트란스글루타미나제 제형 및 이의 제조 방법 | |
| US20010031721A1 (en) | Highly concentrated, lyophilized, and liquid factor IX formulations | |
| ES2906550T3 (es) | Administración subcutánea de ADAMTS13 | |
| ES2218228T3 (es) | Composiciones farmaceuticas de un agente fibrinolitico. | |
| BRPI0919693A2 (pt) | formulação farmacêutica estável liofilizada | |
| RU2155067C2 (ru) | Фармацевтический препарат, содержащий плазминогенактиваторы | |
| ES2241272T3 (es) | Formulaciones para la proteccion de conjugados de peg-interferon alfa. | |
| ES2365832T3 (es) | Composiciones que comprenden conjugados de peg-interferón alfa y rafinosa como crioprotector. | |
| JP2017510585A5 (enExample) | ||
| US20090017007A1 (en) | Liquid factor vii composition | |
| JP5184738B2 (ja) | 修飾第ｖｉｉ因子の安定化された固体組成物 | |
| ES2986574T3 (es) | Tratamiento de hemorragia gastrointestinal en pacientes con enfermedad de von willebrand grave mediante la administración de vwf recombinante | |
| ES2317695T3 (es) | Composiciones secas solubles en agua. | |
| ES2640343T3 (es) | Composición de transglutaminasa anhidra | |
| NZ733837B2 (en) | Pharmaceutical composition comprising plasminogen and uses thereof | |
| AU2004201694B2 (en) | Pharmaceutical compositions of fibrinolytic agent | |
| JPH0378848B2 (enExample) |